# A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07075185/  
OnCo record `nct07075185` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of KLN-1010 run by Kelonia Therapeutics, Inc., now recruiting.

## Summary

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07075185 by Kelonia Therapeutics, Inc., with 70 participants planned, started 2025-07-16. Conditions recorded: Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type, Neoplasm, Hemostatic Disorders, Vascular Disorder, Paraproteinemias, Blood Protein Disorders, Hematologic Disease and Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Disease and Gene Therapy. Interventions recorded: KLN-1010.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07075185
- Phase: 1
- Setting: A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- Sponsor: Kelonia Therapeutics, Inc.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07075185: https://clinicaltrials.gov/study/NCT07075185

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [KLN-1010](https://onco.cc/drugs/kln-1010/)
- companies: [Kelonia Therapeutics](https://onco.cc/companies/kelonia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07075185.json